Abstract
A robust body of information supports the notion that moderately high concentrations of iodine may reduce pathologies in several tissues that concentrate iodine. This paper reviews evidence showing iodine to be an antioxidant and apoptotic agent that may contribute to the differentiation of normal mammary and prostate glands. In animal and human studies, molecular iodine (I2) supplements suppress the development and size of both benign and malignant neoplasias in these glands and significantly reduce cellular lipoperoxidation. Iodine, in addition to its incorporation into thyroid hormones, is bound to antiproliferative iodolipids called iodolactones, which, in conjunction with peroxisome proliferatoractivated receptors, may play a role in controlling proliferative pathologies in mammary and prostate glands. These studies are in line with data demonstrating that the high consumption of iodine by certain Asian populations such as in Japan (25 times more than in the Occident) correlates with a low incidence of benign and cancerous breast and prostate diseases. Based on our data we proposed that an I2 supplement should be considered as an adjuvant in the treatment of pathologies in breast and prostate.
Keywords: Mammary gland, prostate, iodine, cancer, apoptosis, iodolactone, Arachidonic acid, Dihydrotestosterone, Hypoiodite, Iodide, Iodate, Triiodothyronine
Current Chemical Biology
Title: Iodine in Mammary and Prostate Pathologies
Volume: 5 Issue: 3
Author(s): Brenda Anguiano and Carmen Aceves
Affiliation:
Keywords: Mammary gland, prostate, iodine, cancer, apoptosis, iodolactone, Arachidonic acid, Dihydrotestosterone, Hypoiodite, Iodide, Iodate, Triiodothyronine
Abstract: A robust body of information supports the notion that moderately high concentrations of iodine may reduce pathologies in several tissues that concentrate iodine. This paper reviews evidence showing iodine to be an antioxidant and apoptotic agent that may contribute to the differentiation of normal mammary and prostate glands. In animal and human studies, molecular iodine (I2) supplements suppress the development and size of both benign and malignant neoplasias in these glands and significantly reduce cellular lipoperoxidation. Iodine, in addition to its incorporation into thyroid hormones, is bound to antiproliferative iodolipids called iodolactones, which, in conjunction with peroxisome proliferatoractivated receptors, may play a role in controlling proliferative pathologies in mammary and prostate glands. These studies are in line with data demonstrating that the high consumption of iodine by certain Asian populations such as in Japan (25 times more than in the Occident) correlates with a low incidence of benign and cancerous breast and prostate diseases. Based on our data we proposed that an I2 supplement should be considered as an adjuvant in the treatment of pathologies in breast and prostate.
Export Options
About this article
Cite this article as:
Anguiano Brenda and Aceves Carmen, Iodine in Mammary and Prostate Pathologies, Current Chemical Biology 2011; 5 (3) . https://dx.doi.org/10.2174/2212796811105030177
DOI https://dx.doi.org/10.2174/2212796811105030177 |
Print ISSN 2212-7968 |
Publisher Name Bentham Science Publisher |
Online ISSN 1872-3136 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Patents for Homologous Recombination Deficiency Assays Among Women with Ovarian Cancer
Recent Patents on Biotechnology Synthesis, in vitro Antiproliferative and Antiinflammatory Activities, and Kinase Inhibitory effects of New 1,3,4-triarylpyrazole Derivatives
Anti-Cancer Agents in Medicinal Chemistry Juglone: A Versatile Natural Platform for Obtaining New Bioactive Compounds
Current Topics in Medicinal Chemistry Integrins: Novel Therapeutic Targets for Cardiovascular Diseases
Cardiovascular & Hematological Agents in Medicinal Chemistry Advances in Drug Safety
Current Pharmaceutical Design Analogue of Melanotan II (MTII): A Novel Melanotropin with Superpotent Action on Frog Skin
Protein & Peptide Letters Potential Anticancer Properties of Bisphosphonates: Insights From Preclinical Studies
Anti-Cancer Agents in Medicinal Chemistry Precision Genome Editing Techniques in Gene Therapy: Current State and Future Prospects
Current Gene Therapy The Therapeutic Potential of Sigma (σ) Receptors for the Treatment of Central Nervous System Diseases: Evaluation of the Evidence
Current Pharmaceutical Design Pharmacokinetics of Recombinant Human Endostatin in Rats
Current Drug Metabolism Evaluation of Salivary Melatonin Levels in HIV-positive Patients: A Historical Cohort Study
Reviews on Recent Clinical Trials Immunosensors in Early Cancer Diagnostics: From Individual to Multiple Biomarker Assays
Current Medicinal Chemistry Recent Progress in FKBP Ligand Development
Current Molecular Pharmacology Microgravity Alters Cancer Growth and Progression
Current Cancer Drug Targets Duloxetine in the Treatment of Depression: An Overview
Central Nervous System Agents in Medicinal Chemistry Disintegrin Tablysin-15 Suppresses Cancer Hallmarks in Melanoma Cells by Blocking FAK/Akt/ERK and NF-κB Signaling
Current Cancer Drug Targets Marine-derived Trichoderma Species as a Promising Source of Bioactive Secondary Metabolites
Mini-Reviews in Medicinal Chemistry The Current and Evolving Role of Immunotherapy in Metastatic Colorectal Cancer
Current Cancer Drug Targets 4'-Thionucleosides as Potent and Selective A<sub>3</sub> Adenosine Receptor Ligands
Current Organic Chemistry Medical Treatment of Gastrointestinal Stromal Tumors: State of the Art and Future Perspectives
Reviews on Recent Clinical Trials